Julie Kim, President and CEO at Takeda, shared a post on LinkedIn:
“Today marks a truly meaningful moment for people living with polycythemia vera (PV) and for all of us at Takeda who are driven by a simple, powerful purpose of better health and a brighter future.
With the U.S. FDA approval of a new treatment option, we have the opportunity to potentially redefine care for this chronic blood cancer. This milestone is also a testament to the hard work and perseverance of our people who are deeply committed to succeed – and win – for patients.
Our momentum is strong as we achieve another critical milestone in our two-horizon growth journey. Each step expands our impact and deepens the trust we have built over generations.”
You can also read: FDA Approves Takeda’s Mimrylo (Rusfertide) for Polycythemia Vera
